DNA RNA and Cells

23 Feb 2017 OncoSec Announces Positive Phase II Data Demonstrating Company's ImmunoPulse® IL-12 in Combination with Pembrolizumab Increased Response Rates in Anti-PD-1 Non-Responder Melanoma Patients
21 Feb 2017 GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy
17 Feb 2017 Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017
17 Feb 2017 Takeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn’s Disease Patients with Cx601
14 Feb 2017 Ionis Earns $75 Million from Bayer for Advancing IONIS-FXI Rx and IONIS-FXI-L Rx
14 Feb 2017 Sanofi Initiates Phase 2 Clinical Trial to Evaluate Therapy for Genetic Form of Parkinson’s Disease
13 Feb 2017 Transgene and Léon Bérard Cancer Center Announce Dosing of the First Patient in a Phase 1 Immunotherapy Clinical Trial Evaluating the Intra-Tumoral Co-Administration of Pexa-Vec plus Ipilimumab (Yervoy®) in Solid Cancers
10 Feb 2017 VM BioPharma Announces Publication of Phase 1/2 Clinical Data of Novel Gene Therapy VM202 in Amyotrophic Lateral Sclerosis (ALS)
08 Feb 2017 MeiraGTx Provides Clinical Trial Updates for Achromatopsia and Leber's Congenital Amaurosis Ocular Gene Therapy Programs
08 Feb 2017 FDA Grants Cellectis IND Approval to Proceed with the Clinical Development of UCART123, the First Gene Edited Off-the-Shelf CAR T-Cell Product Candidate developed in the U.S.
06 Feb 2017 Sirnaomics Initiates a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar
06 Feb 2017 Kiadis Pharma issues clinical and regulatory progress update on ATIR101™ and ATIR201™
03 Feb 2017 bluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease
01 Feb 2017 Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT342 to Treat Crigler-Najjar Syndrome
31 Jan 2017 Dimension Announces Interim Topline Results from Ongoing Phase 1/2 Clinical Program for DTX101, Dimension’s Lead AAV Product Candidate in Development for Adult Patients with Moderate/Severe to Severe Hemophilia B
31 Jan 2017 ZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells Advancing "Point-of-Care" Approach
31 Jan 2017 TiGenix Enrolls First Patient in Phase Ib/IIa Clinical Trial of Cx611 in Severe Sepsis
30 Jan 2017 uniQure Announces FDA Breakthrough Therapy Designation for AMT-060 in Hemophilia B
30 Jan 2017 Benitec initiates development work on head and neck cancer programs after executing Collaboration Agreement with Nant Capital
26 Jan 2017 SpinalCyte, LLC Enrolls First Patient in Landmark Phase I Human Clinical Trial
25 Jan 2017 Oncolytic Viruses: a still undervalued technology with strong growth perspectives
23 Jan 2017 Cellectis Studies Safety in New CAR Architecture Controlling CAR T-Cell Functions
23 Jan 2017 MOLOGEN AG: Combination data of TLR9 agonist lefitolimod with checkpoint inhibitors in preclinical tumor models
23 Jan 2017 Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of Cancer
18 Jan 2017 Lysogene Receives Rare Pediatric Disease Designation from FDA for LYS-GM101 for Treatment of GM1 Gangliosidosis

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing